Document is current

Any future updates will be listed below

Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

Crossref DOI link: https://doi.org/10.1007/s13555-024-01328-4

Published Online: 2025-01-17

Published Print: 2025-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark